02:53 PM EDT, 03/11/2025 (MT Newswires) -- Arvinas ( ARVN ) and Pfizer ( PFE ) said a phase 3 trial of vepdegestrant to treat advanced or metastatic breast cancer met its primary endpoint in the estrogen receptor 1-mutant population, but failed to reach statistical significance in progression-free survival improvement in the intent-to-treat population.

Arvinas ( ARVN ) shares slumped 51% following a surge in intraday trading volume to over 13.8 million from a daily average of about 1.12 million.

Verizon Communications' ( VZ ) subscriber growth is expected to be "probably soft" in Q1, Chief Revenue Officer Frank Boulben said.

Shares dropped 7%, with intraday trading volume at over 38 million versus a daily average of about 22.9 million.

Morgan Stanley downgraded Afya ( AFYA ) to underweight from equal weight and cut its price target to $17 from $19.

Shares of Afya ( AFYA ) slid 5.7%, with trading volume of over 90,000 shares against a daily average of almost 100,000.

Price: 8.59, Change: -8.97, Percent Change: -51.08